With Rising Variants of COVID and Bird Flu, the Single Broad-Spectrum Antiviral NV-387 Would be the Best Partner for Preparedness, Says NanoViricides' Dr. Diwan
SHELTON, CT / ACCESS Newswire / June 18, 2025 / Dr. Anil Diwan, President of NanoViricides, Inc. (NYSE Amer.: NNVC ) (the "Company"), asserts that with new rising variants of COVID and Bird Flu, the single broad-spectrum antiviral drug NV-387 is well-positioned to support preparedness efforts and to combat potential pandemics.
Nimbus, a new COVID variant, officially NB1.8.1, is displacing the LP8.1 variant that was dominant until a few weeks ago in the USA (https://www.today.com/health/coronavirus/new-covid-variant-nb181-nimbus-symptoms-rcna212304).
Nimbus has been rising globally since Spring according to WHO (https://cdn.who.int/media/docs/default-source/documents/epp/tracking-sars-cov-2/23052025_nb.1.8.1_ire.pdf).
Nimbus causes "razor-sharp" sore throat in some individuals, which is extremely painful and lingering for some time, in addition to the usual COVID symptoms.
Nimbus is more resistant to antibodies generated from previous vaccines, although prior vaccination or natural COVID infection is expected to still be protective in terms reduced severity compared to without such immunity according to CDC.
Nimbus is likely to be more transmissible than the previous variants. It belongs to the JN.1 subfamily of the Omicron family of SARS-CoV-2 virus.
Recently, the Influenza A H5N1 virus from a dairy worker in Michigan was found to be capable of airborne transmission in a ferret animal model [1] (https://www.freep.com/story/news/health/2025/06/05/h5n1-bird-flu-michigan-dairy-farm-airborne-spread-cdc-study/84046550007/). This genotype B3.13 (clade clade 2.3.4.4b) virus in dairy cattle causes moderate severity disease in humans. In contrast, a highly pathogenic genotype D1.1 that is circulating in birds birds has led to one critical month-long illness in Canada and one death in the US signifying the potential for high morbidity and mortality from this genotype if it spreads in humans.
Additionally, a new genotype of H5N1 in Cambodia has caused four fatalities and fifth severe infection as of today (https://www.cidrap.umn.edu/avian-influenza-bird-flu/h5n1-avian-flu-infects-fifth-patient-cambodia).
NV-387, the broad-spectrum antiviral drug is expected to be effective against all of these bird flu viruses. NV-387 was found to be substantially superior to Tamiflu® (Roche, Oseltamivir), Rapivab® (Biocryst, Peramivir), as well as Xofluza (Shionogi/Roche, baloxavir) in lethal lung infection animal model of Influenza infection. All three of these existing anti-influenza drugs are known to be escaped by Influenza viruses by single point mutations in H or PB2 genes.
NV-387 was found to be substantially superior to the approved drug Remdesivir in a lethal coronavirus lung infection animal model for SARS-CoV-2.
Thus the single drug NV-387 alone can combat H5N1, Influenza as well as COVID infections.
NV-387 has completed Phase I clinical trial in healthy human subjects with no reported adverse events.
COVID as well as Influenza viruses readily escape vaccines, antibodies as they change in the field during an epidemic wave. They are also likely to escape small molecule drugs by such changes.
NV-387 takes advantage of the invariant features that these viruses use for causing infection, by mimicking heparan sulfate-like structures. No matter how much these viruses change in the field, they continue to use the heparan sulfate attachment receptors in order to cause infection. Thus it is practically impossible that the viruses may be able escape NV-387 without losing their ability infect and transmit across humans, the Company believes.
NV-387 is orally available, formulated as oral gummies that dissolve in the mouth, thus avoiding issues of inability to swallow which occurs related to sore throat, old age, as well as in young children.
NV-387, as a treatment, is designed to help actually patients with disease recover rapidly, thus limiting the viral spread as well as providing for natural infection-based immunity in the recovered patient.
"NV-387 is thus the best current choice available for a highly cost-effective pandemic preparedness development," said Anil R. Diwan, PhD, President and Executive Chairman of the Company, adding, "We have US-based cGMP manufacturing capabilities already set up as well."
Of note, natural immunity, as induced by recovery from infection, is known to be superior to immunity from subunit and mRNA vaccines. One of the important reasons is that in natural infection, the immune system is subjected to all possible antigens from the entire virus, unlike just the selected antigens or antigen fragments that are present in subunit or mRNA vaccines.
Also, NV-387 can be manufactured in the USA and stockpiled readily at room temperature or refrigeration (for longer periods of time).
Unlike NV-387, vaccines or antibodies would require to be created after the virus takes hold, and they would suffer substantial loss of effectiveness within months after deployment due to changes in the virus. Additionally, vaccines require a cold chain handling. Vaccines also need to be administered to a large proportion of healthy population. There are significant logistical problems with vaccines. There is also the issue of vaccine reluctance, which is a personal choice, as it should be in a free country like the USA.
The broad-spectrum antiviral drug NV-387 was developed specifically to overcome all of these problems. In case of further spread of a severe COVID variant and also a Bird Flu variant in human populations, it will be possible to move NV-387 rapidly into Phase II clinical trial for these diseases, and then prepare for deployment early in the potential pandemic, curtailing its spread.
About NanoViricides
NanoViricides, Inc. (the "Company") (www.nanoviricides.com) is a clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide™ class of drug candidates and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments.
The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company's business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.
Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials.
NV-CoV-2 (API NV-387) is our nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir. NV-CoV-2-R is our other drug candidate for COVID-19 that is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. The Company believes that since remdesivir is already US FDA approved, our drug candidate encapsulating remdesivir is likely to be an approvable drug, if safety is comparable. Remdesivir is developed by Gilead. The Company has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.
The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides' platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company's pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product.
This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.
The phrases "safety", "effectiveness" and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA.
FDA refers to US Food and Drug Administration. IND application refers to "Investigational New Drug" application. cGMP refers to current Good Manufacturing Practices. CMC refers to "Chemistry, Manufacture, and Controls". CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency's (EMA) committee responsible for human medicines. API stands for "Active Pharmaceutical Ingredient". WHO is the World Health Organization. R&D refers to Research and Development.
Contact:NanoViricides, Inc.info@nanoviricides.com
Public Relations Contact:ir@nanoviricides.com
SOURCE: NanoViricides, Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Boston Globe
3 hours ago
- Boston Globe
Mass. considers scrapping religious exemptions for vaccinations
Advertisement In Massachusetts, parents can write a letter stating that a vaccine conflicts with their 'sincerely held religious belief' in order to exempt their children from vaccination requirements needed to enroll in public schools. State Rep. Andy Vargas and State Sen. Edward Kennedy both Advocates who oppose the exemptions say that religious exceptions are being misused by parents who are hesitant about vaccinating their children. Advertisement 'It's definitely a general pattern of people abusing the exemption, especially since But parents across the state came to Beacon Hill to testify in support of religious exemptions at a hearing of the Legislature's Joint Committee on Public Health. They said exemptions were essential to their first amendment right to practice their religion and to honor the concept of informed consent. 'I'm curious why diversity, equity and inclusion is not being applied to those with sincerely held religious beliefs,' Lisa Ottaviano said while testifying at the hearing. Some speakers at the hearing said they were uncomfortable with the components of certain vaccines. 'We should not be forced into violating our moral conscience by injecting products developed from aborted fetuses such as the MMR, the varicella vaccines,' said Nicholas Kottenstette, a Catholic father of four from Sterling, Massachusetts. Vaccines don't contain fetal cells, Others testifying against the bill said they wanted to protect religious exemptions because they felt that accountability measures for vaccine manufacturers were insufficient. 'I started meeting more people whose children had reactions to vaccines that were adverse, so I started doing my own research and learnt a lot of concerning things like how pharmaceutical companies have legal protection against being sued,' Maureen Trettel, a grandmother from Milford said. Advertisement Similar bills have been filed in previous sessions, so the debate over religious exemptions for vaccines in Massachusetts has been going on since at least 2019, well before the COVID-19 pandemic that made vaccines a polarizing issue. The elevation of Robert F. Kennedy Jr., a vaccine skeptic, to U.S. Secretary of Health and Human Services has drawn even more interest to the issue. Last week, Kennedy Logan Beyer, an aspiring pediatrician pursuing an MD/PhD degree in public health at Harvard, spoke in favor of eliminating religious exemptions. While volunteering at a Special Olympics event, Beyer spoke to a parent who told her that she was worried that vaccines caused autism. The mother told Beyer that she was planning to apply for a religious exemption because she was unsure about vaccinating her children. 'She told me that her family 'didn't really go to church' but you don't have to prove anything to get the exemption,' Beyer said. Beyer said that this incident made her concerned about growing vaccine hesitancy and inspired her to testify. 'At the hearing, so many parents said they just want to do what's best for their children … I love that instinct,' Beyer said, 'But I know that passing policies that help facilitate more kids getting vaccinated is really what can keep children safe.' Advertisement Harrison, mother of cancer-survivor Miranda, also understands the instinct of parents on the other side of the issue, even if she disagrees with them. In addition to Miranda, Harrison has twin six-year old boys who both have autism. 'I can know the grief and shock that parents experience when they find out their kid has autism. I get it,' Harrison said. 'But vaccines are not to blame ... autism is a result of Around 16,000 children in Massachusetts are unvaccinated without claiming an exemption — a group that the state describes as 'noncompliant students' in its documents. Many parents in opposition to the bills questioned why the bills were trained just on the 2,000 students who did have religious exemptions. 'I'm curious why the Legislature is targeting the small percentage of children with religious exemptions and ignoring the huge gap population,' said Ottaviano testifying at the hearing. Advocates for the bills said the new provisions that mandate that all schools must report vaccination numbers to the state's department of public health would address these noncompliant students as well. 'That's what the data reporting is about, we want to make sure that schools have accurate records,' Blair of Massachusetts Families for Vaccines said. 'If there is a gap … they should reach out to those students to find out why the records are not on file.' Speakers in favor of the bills were focused on eliminating religious exemptions in order to protect children who cannot be vaccinated due to medical reasons like allergies or problems with their immune systems. 'It's actually those people … that we're really doing this for, because they're the ones who depend on herd immunity,' Blair said. Advertisement Angela Mathew can be reached at
New York Times
8 hours ago
- New York Times
‘I Feel Like I've Been Lied To': When a Measles Outbreak Hits Home
He was a chiropractor by training, but in a remote part of West Texas with limited medical care, Kiley Timmons had become a first stop for whatever hurt. Ear infections. Labor pains. Oil workers who arrived with broken ribs and farmers with bulging discs. For more than a decade, Kiley, 48, had seen 20 patients each day at his small clinic located between a church and a gas station in Brownfield, population 8,500. He treated what he could, referred others to physicians and prayed over the rest. It wasn't until early this spring that he started to notice something unfamiliar coming through the door: aches that lingered, fevers that wouldn't break, discolored patches of skin that didn't make sense. At first, he blamed it on a bad flu season, but the symptoms stuck around and then multiplied. By late March, a third of his patients were telling him about relatives who couldn't breathe. And then Kiley started coughing, too. His wife, Carrollyn, had recently tested positive for Covid, but her symptoms eased as Kiley's intensified. He went to a doctor at the beginning of April for a viral panel, but every result came back negative. The doctor decided to test for the remote possibility of measles, since there was a large outbreak spreading through a Mennonite community 40 miles away, but Kiley was vaccinated. 'I feel like I'm dying,' Kiley texted a friend. He couldn't hold down food or water. He had already lost 10 pounds. His chest went numb, and his arms began to tingle. His oxygen was dropping dangerously low when he finally got the results. 'Positive for measles,' he wrote to his sister, in mid-April. 'Just miserable. I can't believe this.' Twenty-five years after measles was officially declared eliminated from the United States, this spring marked a harrowing time of rediscovery. A cluster of cases that began at a Mennonite church in West Texas expanded into one of the largest outbreaks in a generation, spreading through communities with declining vaccination rates as three people died and dozens more were hospitalized from Mexico to North Dakota. Public health officials tracked about 1,200 confirmed cases and countless exposures across more than 30 states. People who were contagious with measles boarded domestic flights, shopped at Walmart, played tuba in a town parade and toured the Mall of America. Want all of The Times? Subscribe.
Associated Press
17 hours ago
- Associated Press
Does Hospital Indemnity Insurance Help Cover Recurring Stays?
NEW YORK, NY / ACCESS Newswire / June 21, 2025 / A three-day stay in the hospital costs an average of $30,000 in the United States.1 While health insurance can help reduce your out-of-pocket costs if you have to be admitted to the hospital, there are contingent costs that may not be covered by your insurer. The cost of hospital stays, and other expenses like childcare could have a significant impact while you are unable to work. A hospital indemnity insurance policy can help with these costs. Here, we explore what health insurance helps cover and how the cash benefits of hospital indemnity insurance can help fill coverage gaps relating to recurring hospital stays. What does health insurance help cover? Many people receive health insurance through their employer, which can help with the cost of a hospital stay. Employer-sponsored health insurance plans cost an average of $111 per month, while Marketplace plans cost an average of $456 per month.2 So, if you're wondering, " How much is health insurance ?,' the answer depends on your specific circumstances and plan options. Marketplace health insurance plans typically cover a range of essential health benefits, including:3 Outpatient services Emergency services Hospitalization for surgery or overnight stays Pregnancy, maternity and newborn care Mental health and behavioral health treatment Prescription drugs Rehabilitative and habilitative services and devices Laboratory services Preventive and wellness services Chronic disease management Pediatric services Hospital costs are usually covered at least in part by primary health insurance plans, but you'll still have to pay copays and deductibles, and your health insurance plan may be subject to coverage limits. What is hospital indemnity insurance? Hospital indemnity insurance is a supplemental plan that can help fill gaps in your primary health insurance. It's not a replacement for health insurance but can help you with unexpected expenses and provide additional support if you've had multiple hospital stays that forced you to reach a coverage limit. Hospital indemnity insurance works similarly to health insurance in that you pay premiums to an insurance provider in exchange for coverage. You may have access to a plan through your employer, or you can purchase an individual plan directly from an insurance company. Unlike health insurance, however, hospital indemnity insurance plans typically pay eligible cash benefits based on the policy option you choose. You can use the benefits in any way you see fit, such as: Out-of-pocket medical expenses Childcare Living expenses like groceries, rent and utilities Plans may function differently between providers, but typically, you can file a claim for care provided while in the hospital, and your insurance provider pays eligible claims to help you with the costs of your hospital stay. Why is hospital indemnity insurance worth it? There are a number of reasons why you might consider a hospital indemnity insurance plan. These may include: Added financial assistance: Hospital stays can be expensive, especially if you have to go multiple times in the same year. Hospital indemnity insurance helps provide added financial support for recurring visits. Flexibility: Health insurance plans typically pay the hospital directly for treatment. But hospital indemnity insurance pays cash benefits direct to the policyholder, unless otherwise assigned, so you can use it for both medical and non-medical costs. Surpassing coverage limits: If you've reached a health insurance coverage limit after being admitted to the hospital several times, you could still use the hospital indemnity insurance. Ultimately, if you think you or a family member will have multiple stays at the hospital in a given year, hospital indemnity insurance could help provide some added peace of mind. The bottom line Hospital indemnity insurance provides coverage options that can help with recurring hospital stays. This supplemental policy pays cash benefits direct to the policyholder, unless otherwise assigned, so you can use your benefits to help fill gaps in your health insurance coverage or help pay living expenses. Consider applying for a hospital indemnity insurance policy for added peace of mind. Sources: 1 - Why health insurance is important. Accessed May 12, 2025. 2 Ramsey Solutions - How Much Does Health Insurance Cost? Updated May 12, 2025. Accessed May 12, 2025. 3 - Health benefits & coverage. Accessed May 12, 2025. Content within this article is provided for general informational purposes and is not provided as tax, legal, health, or financial advice for any person or for any specific situation. Employers, employees, and other individuals should contact their own advisers about their situations. For complete details, including availability and costs of Aflac insurance, please contact your local Aflac agent. Aflac coverage is underwritten by American Family Life Assurance Company of Columbus. In New York, Aflac coverage is underwritten by American Family Life Assurance Company of New York. Hospital, B40000 series: In Delaware, Policies B40100DE & B4010HDE. In Idaho, Policies B40100ID & B4010HID. In Oklahoma, Policies B40100OK & B4010HOK. In Pennsylvania, Policies B40100PA & B4010HPA. In Virginia, Policies B40100VA & B4010HVA. Coverage may not be available in all states, including but not limited to DE, ID, NJ, NM, NY, VA or VT. Benefits/premium rates may vary based on state and plan levels. Optional riders may be available at an additional cost. Policies and riders may also contain a waiting period. Refer to the exact policy and rider forms for benefit details, definitions, limitations, and exclusions. Aflac WWHQ | 1932 Wynnton Road | Columbus, GA 31999 CONTACT: Senior PR & Corporate Communications Contact: Angie Blackmar, 706-392-2097 or [email protected] SOURCE: Aflac press release
